Medication info
Duo Tablet Sustained Release 10/500 mg

Duo Tablet Sustained Release 10/500 mg

Prescription medicationTabletOral
Ingredient · strength
Metformin Hydrochloride›500mg / 1 tabletDapagliflozin Propanediol Hydrate›12.3mg / 1 tablet
Manufacturer / importer
AstraZeneca Korea
Appearance
Pink, biconvex, rectangular film-coated tablet
Packaging
30 tablets/box [(6 tablets/PTP)x5], 28 tablets/box [(7 tablets/PTP)x4]
Approval status
Active

MFDS item code 201503635 · Approved 2015.06.08 · Insurance code 650700960

Summary

Main use
Improvement of glycemic control in adults with type 2 diabetes
Who takes it
Adults
Adult dose
The dose of this medicine should be individualized based on the patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of dapagliflozin 10mg and extended-release metformin 2000mg. This medicine is generally administered once daily with the evening meal. The maximum dose of this medicine is dapagliflozin 10mg/extended-release metformin 2000mg once daily, administered as two 5mg/1000mg tablets. For patients with no previous history of antidiabetic drug treatment and inadequate glycemic control with monotherapy: When used as initial therapy in patients with no previous history of antidiabetic drug treatment, the recommended starting dose of this medicine is one 5mg/500mg or 10mg/500mg tablet once daily. Titrate the dose gradually to reduce gastrointestinal adverse reactions associated with metformin. For patients switching from concomitant dapagliflozin and metformin therapy to this medicine, the dose may be started at the doses of dapagliflozin and metformin previously being taken. When switching from immediate-release to extended-release metformin, glycemic control should be closely monitored and dosage adjusted appropriately. The safety and efficacy of this medicine have not been specifically evaluated in patients switching from other antihyperglycemic agents. Because changes may result in altered glycemic control, any change in the treatment of patients with type 2 diabetes should be made with careful monitoring. This medicine must be swallowed whole and must never be crushed, cut, or chewed. Occasionally, the inactive ingredients of this medicine may be excreted in the stool as a soft, hydrated mass resembling a tablet. Renal impairment No dosage adjustment is required in patients with mild renal impairment. For patients with an estimated glomerular filtration rate (eGFR) of 45 mL/min/1.73 m2 or more and less than 60 mL/min/1.73 m2, without other conditions that may increase the risk of lactic acidosis, the starting dose of metformin hydrochloride, a component of this medicine, is 500mg once daily, and the maximum daily dose is 1000mg. Administration of this medicine is not recommended in patients with eGFR below 45 mL/min/1.73m2. If the estimated glomerular filtration rate (eGFR) falls below 45 mL/min/1.73m2, discontinue this medicine immediately. Renal function should be assessed every 3~6 months. Elderly patients Because metformin is excreted through the kidneys and renal function is more likely to be reduced in elderly patients, this medicine should be used with caution as age increases (see Precautions for Use, 9. Administration to Elderly Patients).

Ingredients

Importer
AstraZeneca Korea

Efficacy & effects

Improvement of glycemic control in adults with type 2 diabetes

  • Type 2 diabetes
  • abnormal blood sugar control
  • cardiovascular disease
  • cardiovascular risk factors
View approved original text

This medication helps improve blood sugar control in adult patients with type 2 diabetes by using dapagliflozin and metformin together. It is more effective when used in conjunction with diet and exercise. Especially in patients with type 2 diabetes who have cardiovascular disease or risk factors and are not well-controlled, it is important to consult a specialist regarding the impact of dapagliflozin on the occurrence of cardiovascular diseases and refer to relevant clinical information. This medication is effectively used for diabetes treatment and blood sugar control.

How to take

Adult dose

The dose of this medicine should be individualized based on the patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of dapagliflozin 10mg and extended-release metformin 2000mg. This medicine is generally administered once daily with the evening meal. The maximum dose of this medicine is dapagliflozin 10mg/extended-release metformin 2000mg once daily, administered as two 5mg/1000mg tablets. For patients with no previous history of antidiabetic drug treatment and inadequate glycemic control with monotherapy: When used as initial therapy in patients with no previous history of antidiabetic drug treatment, the recommended starting dose of this medicine is one 5mg/500mg or 10mg/500mg tablet once daily. Titrate the dose gradually to reduce gastrointestinal adverse reactions associated with metformin. For patients switching from concomitant dapagliflozin and metformin therapy to this medicine, the dose may be started at the doses of dapagliflozin and metformin previously being taken. When switching from immediate-release to extended-release metformin, glycemic control should be closely monitored and dosage adjusted appropriately. The safety and efficacy of this medicine have not been specifically evaluated in patients switching from other antihyperglycemic agents. Because changes may result in altered glycemic control, any change in the treatment of patients with type 2 diabetes should be made with careful monitoring. This medicine must be swallowed whole and must never be crushed, cut, or chewed. Occasionally, the inactive ingredients of this medicine may be excreted in the stool as a soft, hydrated mass resembling a tablet. Renal impairment No dosage adjustment is required in patients with mild renal impairment. For patients with an estimated glomerular filtration rate (eGFR) of 45 mL/min/1.73 m2 or more and less than 60 mL/min/1.73 m2, without other conditions that may increase the risk of lactic acidosis, the starting dose of metformin hydrochloride, a component of this medicine, is 500mg once daily, and the maximum daily dose is 1000mg. Administration of this medicine is not recommended in patients with eGFR below 45 mL/min/1.73m2. If the estimated glomerular filtration rate (eGFR) falls below 45 mL/min/1.73m2, discontinue this medicine immediately. Renal function should be assessed every 3~6 months. Elderly patients Because metformin is excreted through the kidneys and renal function is more likely to be reduced in elderly patients, this medicine should be used with caution as age increases (see Precautions for Use, 9. Administration to Elderly Patients).

Precautions

This medication is used for the treatment of diabetes and contains two components: metformin and dapagliflozin. When taking this medication, caution is advised as lactic acidosis, a serious side effect, can occur very rarely. Lactic acidosis is a condition where excessive lactic acid accumulates in the body, which can be life-threatening. Also, there is a risk of hypoglycemia when taken with insulin or sulfonylurea medications, so blood sugar levels should be closely monitored. Patients with poor kidney function, dehydration, severe infections, or decreased heart function should not take this medication. Patients whose kidney function is moderate to severely impaired, as well as those with acute illnesses or scheduled surgeries, should discontinue taking this medication and can begin again only after confirming normal kidney function. Women who are pregnant or breastfeeding and patients with certain genetic disorders such as lactose intolerance should not take this medication. This medication should be administered with caution to patients at risk of volume depletion or hypotension, and elderly patients or those with decreased kidney function should be particularly careful. While taking this medication, there may be interactions with other medications that can affect blood sugar control, so all medications being taken should be disclosed to healthcare providers. During the use of this medication, genital infections or urinary tract infections may occur, so if symptoms of infection appear, immediate consultation with healthcare providers is necessary. Moreover, vitamin B12 deficiency may occur, so it is advisable to monitor blood vitamin B12 levels during prolonged use. Excessive alcohol consumption may increase the risk of side effects from this medication, so it should be avoided. This medication has not been established for safety and efficacy in children, so it is not used for them. Dizziness or hypotensive symptoms may occur during use, so caution is advised when driving or operating machinery. Lastly, this medication should be stored out of reach of children and should be kept in its original container for safety.

Side effects

  • Severe lactic acidosis
  • severe hypoglycemia
  • vulvovaginitis
  • balanitis
  • genital infection
  • urinary tract infection
  • fungal infection
  • hypoglycemia
  • decreased fluid volume
  • thirst
Show 85 more
  • diabetic ketoacidosis
  • dizziness
  • constipation
  • dry mouth
  • back pain
  • dysuria
  • polyuria
  • nocturia
  • vulvar pruritus
  • genital pruritus
  • increased hematocrit
  • decreased renal creatinine clearance
  • dyslipidemia
  • increased blood creatinine
  • increased blood urea
  • weight loss
  • ketoacidosis
  • urosepsis
  • pyelonephritis
  • acute kidney injury
  • renal dysfunction
  • rash
  • diarrhea
  • nausea
  • vomiting
  • decreased vitamin B12
  • Guillain-Barré syndrome
  • bacterial pneumonia
  • sialadenitis
  • tendinitis
  • chest pain
  • thermal burn
  • wrist fracture
  • gastrointestinal stromal tumor
  • lung malignancy
  • uterine fibroids
  • atrial fibrillation
  • acute cholecystitis
  • epigastric pain
  • dyspepsia
  • abdominal discomfort
  • abdominal pain
  • gastric ulcer
  • irritable bowel syndrome
  • salivary gland mass
  • toothache
  • headache
  • facial paralysis
  • peripheral neuropathy
  • paresthesia
  • drowsiness
  • tremor
  • nasopharyngitis
  • pharyngitis
  • adenoviral conjunctivitis
  • herpes zoster
  • pneumonia
  • rhinitis
  • increased alanine aminotransferase
  • increased blood sugar
  • arthralgia
  • myalgia
  • myofascial pain syndrome
  • osteoarthritis
  • osteochondrosis
  • limb pain
  • periarticular inflammation
  • tenosynovitis
  • trigger finger
  • myasthenia
  • fatigue
  • peripheral edema
  • swelling
  • pain
  • vitamin D deficiency
  • hyperglycemia
  • urethral syndrome
  • cough
  • hyperventilation
  • skin abrasion
  • pruritus
  • palpitations
  • insomnia
  • type 2a hyperlipidemia
  • sensorineural hearing loss

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to protect it from air and moisture. The storage temperature should ideally be maintained at room temperature between 1 degree and 30 degrees Celsius.

Appearance and packaging

Appearance

Pink, biconvex, rectangular film-coated tablet

Package unit

30 tablets/box [(6 tablets/PTP)x5], 28 tablets/box [(7 tablets/PTP)x4]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.